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Abstract
The metastasis-associated tyrosine phosphatase PRL-3/PTP4A is upregulated in numerous cancers, but the mechanisms
modulating PRL-3 activity other than its expression levels have not been investigated. Here we report evidence for both Src-
dependent tyrosine phosphorylation of PRL-3 and Src-mediated regulation of PRL-3 biological activities. We used structural
mutants, pharmacological inhibitors and siRNA to demonstrate Src-dependent phosphorylation of endogenous PRL-3 in
SW480 colon cancer cells. We also demonstrated that PRL-3 was not tyrosine phosphorylated in SYF mouse embryo
fibroblasts deficient in Src, Yes and Fyn unless Src was re-expressed. Further, we show that platelet-derived growth factor
(PDGF) can stimulate PRL-3 phosphorylation in a Src-dependent manner. Finally, we show that PRL-3-induced cell motility,
Matrigel invasion and activation of the cytoskeleton-regulating small GTPase RhoC were abrogated in the presence of the
phosphodeficient PRL-3 mutant Y53F, or by use of a Src inhibitor. Thus, PRL-3 requires the activity of a Src kinase, likely Src
itself, to promote these cancer-associated phenotypes. Our data establish a model for the regulation of PRL-3 by Src that
supports the possibility of their coordinate roles in signaling pathways promoting invasion and metastasis, and supports
simultaneous use of novel molecularly targeted therapeutics directed at these proteins.
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Introduction
Extensive evidence has accumulated linking the putative
tyrosine phosphatase PRL-3 with invasion and metastasis
(reviewed in [1–3]). Although the precise roster of its substrates
remains to be fully determined, it is clear that PRL-3 mediated
biological activities require its phosphatase activity and its lipid
modification by farnesylation, as mutation of the catalytic residue
C104 or the prenylated CAAX motif abrogates these functions [4–
8]. However, little is known concerning the mechanism(s) through
which PRL-3 itself is regulated, and it has largely been assumed
that both its biochemical and biological activity correlate solely
with its expression. Numerous studies have examined relative
PRL-3 expression levels in cancer versus normal cells or tissues [1–
3]. Other studies have demonstrated, for example, control of PRL-
3 transcription by p53 [9], Snail [10], or MEF2C [11]; PCBP1-
mediated control of PRL-3 translation [12]; and FKBP38-
mediated control of PRL-3 protein stability [13]. One possible
mechanism of regulation other than expression levels is post-
translational modification of PRL-3, such as phosphorylation. In
support of this possibility, there is evidence for the regulation of
tyrosine phosphatases downstream of tyrosine kinases, including
the proto-oncogene Src. For example, low molecular weight
protein tyrosine phosphatase (LMW-PTP) is phosphorylated by
Src [14], as well as by Fyn and Lck [15], and the EphA8 receptor
tyrosine kinase [16]. This modification affects both the catalytic
activity of LMW-PTP [16–18] and its association with the adapter
protein Grb2 [17]. Similarly, phosphorylation of PTP1B by the
insulin receptor [19,20] or c-Met receptor [21] affects its catalytic
activity, and phosphorylation of SHP-1 and SHP-2 lead to
increases in their catalytic activity [22] and signaling [23,24].
Interestingly, PRL-1, which shares all six tyrosines in common
with PRL-3, was shown to be phosphorylated by Src in vitro [25],
suggesting that PRL phosphatases may also be regulated by Src
family kinases.
We therefore set out to determine a possible role for Src-
mediated phosphorylation in the regulation of PRL-3 activity.
Whether PRL-3 is phosphorylated by Src kinases was not known,
nor were the potential functional consequences of such phosphor-
ylation to any PRL family member examined. Here we report that
PRL-3 is phosphorylated both in vitro and in vivo downstream of
Src, and that this phosphorylation is required for PRL-3 to
promote invasion, motility and activation of RhoC in cell culture
systems. We also show that PRL-3 phosphorylation is stimulated
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by PDGF in a Src-dependent manner. Together these observa-
tions support a model in which Src, and possibly members of the
PDGF receptor family, acts upstream of PRL-3 to promote
invasion, and further suggest that PRL-3 may mediate some of the
invasion and metastasis-associated functions of PDGFR, Src or
related kinases.
Methods
Cell lines, plasmids, transfections and antibodies
SW480 colon adenocarcinoma cells and H1299 nonsmall cell
lung cancer cells were obtained from the UNC-Lineberger
Comprehensive Cancer Center Tissue Culture Facility. Src/
Yes/Fyn-deficient (SYF) mouse embryo fibroblast (MEF) cells [26]
were a gift from Ken Jacobson (UNC). SW480 cells were
maintained in 0% CO2 in Leibovitz L15 medium (with glutamine)
supplemented with 10% fetal calf serum. SYF and H1299 cells
were maintained in 10% CO2 in Dulbecco’s modified Eagle
medium with high glucose (DMEM-H) supplemented with 10%
fetal calf serum. To generate mammalian expression plasmids
(pSBP-PRL-3) encoding fusion proteins that could be pulled down
using streptavidin-Sepharose (GE Healthcare, Uppsala, Sweden),
coding sequences for PRL-3 and mutants were cloned into pSBP,
a pcDNA3-based vector into which we had previously inserted
streptavidin-binding protein (SBP). All transfections were per-
formed on 50–60% confluent cells plated in 100 mm dishes, with
1 mg each of the indicated plasmid(s), using the transfection
reagent TransIT-LT1 (Mirus) according to the manufacturer’s
protocol.
For bacterial expression, PRL-3 or mutants were cloned into
pGEX2T (GE Healthcare) fused to glutathione-S-transferase
(GST). To generate SW480 cells stably expressing PRL-3 or
mutants, coding sequences were cloned into pBABE-HAII. pUSE-
Src was obtained from Upstate Biotechnology (Lake Placid, NY).
Western blot analyses were done with the following antibodies:
anti-PRL-3 (P-0498, Sigma, St. Louis, MO), pY99 anti-phospho-
tyrosine (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Src
antibody (32G6) and anti-phospho-Src family Tyr 416 antibody
(#2101, Cell Signaling Technologies, Danvers, MA) and anti-
RhoC (a kind gift from K. Van Golen, University of Delaware)
[27].
Endogenous PRL-3 immunoprecipitation and treatment
with platelet-derived growth factor (PDGF)
To evaluate endogenous PRL-3 phosphorylation, cells were
treated for 1 h with 100 mM pervanadate. Pervanadate was made
fresh by adding 1 mL of 30% hydrogen peroxide to 200 mL of
50 mM sodium orthovanadate in water. Following treatment, cells
were lysed in RIPA (50 mM Tris, pH 8.0, 150 mM sodium
chloride, 1% Nonidet P-40 substitute, 0.5% deoxycholate, 0.1%
sodium dodecylsulfate) +100 mM pervanadate and protease
inhibitors. PRL-3 antibody (Sigma-Aldrich, St. Louis, MO) was
diluted 1:250 in lysates containing 200-500 mg total protein.
Samples were incubated at 4uC O/N with rocking. Immune
complexes were precipitated with protein A/G Sepharose, washed
three times in RIPA, and resuspended in protein gel sample buffer
without reducing agents prior to SDS-PAGE and western blot
analysis. For treatment with PDGF, SW480 cells were starved
overnight in the absence of serum. Cells were then treated with the
Src inhibitor SU6656 (1, 5, or 10 mM; Calbiochem, San Diego,
CA)) or with vehicle (DMSO) for 1 h. Alternatively, Src expression
was ablated using siRNA as described below, and serum starved
overnight prior to PDGF treatment. Cells were then treated for
20 min with human PDGF-BB (Sigma, 20 ng/mL) and lysed for
PRL-3 immunoprecipitation as described above.
siRNA-mediated knockdown of Src
Expression of endogenous Src was reduced using an siRNA
pool containing four targeting sequences (Dharmacon/Thermo
Fisher Scientific, Rockford, IL). SW480 cells were transfected
according to the manufacturer’s protocol using a final siRNA
concentration of 50 nM. The Dharmacon ON-TARGETplus non-
targeting siRNA pool was used as a negative control. Cells were
maintained in standard conditions for five days and treated with
pervanadate for 1 h prior to lysis and PRL-3 immunopreciptiation
as described above.
Exogenous PRL-3 pull downs
Following treatment, cells were lysed in streptavidin lysis buffer
(SLB: 10 mM Tris, pH 8.0, 150 mM sodium chloride, 0.1% NP-
40). To pull down and detect SBP-tagged PRL-3, streptavidin-
Sepharose beads were incubated with clarified lysates for 1 h at
4uC with rocking, washed three times with SLB and subjected to
SDS-PAGE and western blot analysis using anti-PRL-3 antibody.
For inhibitor studies, the Src family kinase inhibitor SU6656 was
added to the culture medium 1 h prior to pervanadate treatment.
In vitro Src kinase assays
GST-tagged PRL-3 was induced from the pGEX2T vector in
E. coli bacteria, purified on glutathione beads, and subjected to in
vitro phosphorylation by purified p60 c-Src (14–117, Millipore,
Inc., Billerica, MA). The in vitro kinase assay was carried out with
,500 ng of each protein according to the manufacturer’s
protocol, except that non-radiolabelled ATP was used as the
phosphate donor. Samples were then subjected to SDS-PAGE and
western blot analysis for phosphotyrosine and for PRL-3.
Matrigel invasion assays
The invasiveness of SW480 cells stably expressing PRL-3 or a
phosphodeficient mutant (PRL-3 Y53F) was evaluated using
Matrigel invasion chambers (BD Biosciences, Bedford, MA) as
described previously [4]. SW480 cells (56104/well) were placed in
the top section of the invasion chamber in the absence of serum.
Medium containing 10% serum was placed in the bottom
chamber to create a chemoattractant gradient. After 72 h invaded
cells were stained and counted. For inhibitor studies, SU6656 was
placed in both the top and bottom chambers. Data were analyzed
using a two-tailed Student’s t-test.
Single cell motility assays
The effect of PRL-3 and the phospho-deficient mutant Y53F on
cell motility was evaluated using a Nikon BioStation IM single cell
recorder. H1299 cells (76103 cells/plate), whose basal adhesive and
motile characteristics are suitable for this assay system, were plated
on glass-bottom plates (MatTek, Ashlan, MA) and transfected with
EGFP-tagged PRL-3, PRL-3 (Y53F) or empty vector. Time-lapse
images of fluorescent cells were taken at 5 min intervals over 2 h.
Average velocity of individual cells was evaluated using ImageJ
(http://rsb.info.nih.gov/ij/). Non-fluorescent cells were also evalu-
ated as controls. Data were analyzed using a two-tailed Student’s
t-test.
RhoC activity assays
Levels of active RhoC-GTP were determined as previously
described [4]. Briefly, SW480 cells stably expressing PRL-3 or
mutants were starved in 0% serum overnight prior to lysis. Lysates
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containing 500-750 mg total protein were incubated at 4uC for 1 h
with glutathione agarose beads carrying the GST-tagged Rho-
binding domain of the RhoC effector, Rhotekin (GST-RBD,
,100 mg). The beads were pelleted and subjected to western blot
analysis for RhoC. For inhibitor studies, SU6656 was added 1 h
prior to lysis.
Results
PRL-3 is phosphoryated in vitro by the Src tyrosine
kinase, and endogenous PRL-3 is tyrosine-
phosphorylated in cells
Many cellular proteins, including some tyrosine phosphatases,
are regulated by phosphorylation on tyrosine residues [14–21].
The tyrosine phosphatase PRL-1, which shares all six tyrosine
residues in common with its close relative, PRL-3, has been shown
to be phosphorylated in vitro by the tyrosine kinase Src [25],
although the study did not determine the site of phosphorylation
or whether it occurs in vivo. Analysis of PRL-3 using Netphos 2.0
(http://www.cbs.dtu.dk/services/NetPhos/) indicated a high
probability of PRL-3 phosphorylation on tyrosines (Figure 1A).
To determine whether Src can phosphorylate PRL-3 as it does
PRL-1, we first performed an in vitro kinase assay in which
bacterially expressed PRL-3 fused to glutathione-S-transferase
(GST-PRL-3) was subjected to phosphorylation by purified Src.
Using western blot analysis with anti-phosphotyrosine antibody,
we observed that WT PRL-3 was phosphorylated on tyrosine in
the presence of Src, whereas a mutant form of PRL-3 lacking all
six tyrosines (designated ‘‘All_F’’) was not (Figure 1B). We
obtained identical results when the kinase assay was performed
using 32P-ATP and phosphorylation was evaluated by autoradi-
ography (data not shown). In neither case was GST alone
phosphorylated (data not shown). Thus, PRL-3, like PRL-1, can
be a direct substrate of Src tyrosine kinase activity in vitro.
We next wished to determine whether PRL-3 is also tyrosine
phosphorylated in cells. We have shown previously that PRL-3
promotes motility and invasion in SW480 colon adenocarcinoma
cells[4], properties that are also regulated by Src. Therefore, we
treated SW480 cells, which express PRL-3 endogenously, with the
tyrosine phosphatase inhibitor pervanadate to prevent dephos-
phorylation and thereby to promote the accumulation of
phosphorylated PRL-3. Following immunoprecipitation using an
anti-PRL-3 antibody, we performed western blot analysis for
phosphotyrosine. Figure 1C shows that endogenous PRL-3 can be
phosphorylated on tyrosine. The lack of detectable basal tyrosine
phosphorylation in the absence of pervanadate suggests that this
phosphorylation event is transient, evident only when the cellular
phosphatase(s) responsible for dephosphorylation are blocked.
Src is required for PRL-3 tyrosine phosphorylation
Src regulates some tyrosine phosphatases in vivo, either directly
or indirectly [14,17]. Having shown that PRL-3 can be a direct
substrate of Src tyrosine kinase activity in vitro and that endogenous
PRL-3 is tyrosine phosphorylated in vivo, we wished to determine
the role of Src in modulating PRL-3 phosphorylation. First, to
determine whether Src is sufficient to cause an increase in PRL-3
tyrosine phosphorylation, we co-transfected SW480 cells with both
PRL-3 and Src, then probed for tyrosine phosphorylation of PRL-
3 by western blot analysis. Figure 2A shows that, even in the
absence of pervanadate-mediated inhibition of dephosphorylation,
tyrosine phosphorylation of PRL-3 was easily detectable in the
presence of Src but not with empty vector alone (V). Although
Figure 1. PRL-3 is phosphoryated in vitro by the Src tyrosine kinase, and endogenous PRL-3 is tyrosine-phosphorylated in cells. A)
Schematic diagram of PRL-3 showing the relative positions of the six tyrosines evaluated in these studies, as well as the C-terminal CaaX motif. The
numbers shown reflect the probability of phosphorylation at each site based on predictions by NetPhos 2.0. B) PRL-3 (‘‘WT’’) or a mutant in which all
six tyrosines were substituted by phenylalanine (‘‘All_F’’) was fused to GST, purified from bacteria, and subjected to in vitro phosphorylation with
purified Src. WT PRL-3 was phosphorylated by Src while the ‘‘All_F’’ PRL-3 mutant was not. Src itself is visible on the phosphotyrosine blot because it
becomes autophosphorylated on Y416 (pSrc). Coomassie staining demonstrates equal amounts of PRL-3 protein in each reaction. C) To determine
whether endogenous PRL-3 is also tyrosine phosphorylated in cells, SW480 cells were treated with the tyrosine phosphatase inhibitor pervanadate
(VO4, 100 mM, 1 h) to enhance detection of transient tyrosine phosphorylation events. Endogenous PRL-3 was immunoprecipitated using anti-PRL-3
antibody, followed by SDS-PAGE and western blot analysis for either PRL-3 or phosphotyrosine.
doi:10.1371/journal.pone.0064309.g001
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these results do not indicate whether PRL-3 is a direct or indirect
target of Src, and indeed unequivocal demonstration of a direct
relationship between kinase and substrate in cells is technically not
feasible with currently available technology, they do indicate that
Src can act upstream of PRL-3 and is sufficient to mediate its
tyrosine phosphorylation in cells. Of course, these results do not
rule out a role for other tyrosine kinases in modulating PRL-3
function, whether in addition to or in place of Src itself.
To confirm the importance of Src as a modulator of PRL-3
phosphorylation, we next performed a complementary experiment
in which we transfected PRL-3 into SYF cells, which are MEFs
that are simultaneously deficient in expression both of Src and of
the related Src family kinases Yes and Fyn [26]. We then treated
these cells with the phosphatase inhibitor pervanadate to reveal
phosphorylated PRL-3. SYF cells displayed a low level of PRL-3
tyrosine phosphorylation, which was greatly increased by the
stable reintroduction of Src (SYF+Src) (Figure 2B). These results
confirm that Src itself is capable of promoting the phosphorylation
of PRL-3. It is not clear whether the reduced levels of total
exogenous PRL-3 protein seen consistently in SYF+Src compared
to SYF cells result from effects of Src on PRL-3 expression,
stability or some other factor. However, PRL-3 expression does
not correlate with PRL-3 phosphorylation (compare Figure 2B,
lanes 1 and 2, or lanes 3 and 4), indicating that phosphorylation is
unlikely to affect protein stability, for example. Alternatively, Src
expression in SYF+Src cells might decrease transcription of
exogenous PRL-3 message, although it is not clear how Src
activity would affect transcription driven by the strong cytomeg-
alovirus (CMV) promoter in the PRL-3 expression plasmid. We
conclude that this observation may be an artifact of the
experimental conditions.
We observed that vanadate was not required to detect
phosphorylation of PRL-3 by Src in SW480 cells (Figure 2A)
whereas it was required in SYF cells (Figure 2B). We speculate that
SW480 cells, which are derived from a primary colon tumor and
express a transformed phenotype, activate WT Src more
effectively than untransformed, MEF-derived SYF cells, and
thereby induce basal levels of Src activity and PRL-3 phosphor-
ylation sufficient to detect without inhibition of dephosphorylation.
To determine whether Src is necessary for PRL-3 tyrosine
phosphorylation, we pretreated SW480 cells with the Src family
kinase (SFK) inhibitor SU6656 (10 mM or 1 mM, 1 h), followed by
treatment with pervanadate to reveal phosphorylation of endog-
enous PRL-3 as done for Figure 1B. Whereas pervanadate caused
accumulation of phospho-PRL-3 in the presence of vehicle only,
SU6656 inhibited PRL-3 phosphorylation in a dose-dependent
manner, such that 1 mM inhibited phosphorylation by ,20% and
no phospho-PRL-3 was detected in the presence of 10 mM of this
SFK inhibitor (Figure 2C). This indicates that phosphorylation of
endogenous PRL-3 requires the activity of at least one member of
the Src family of tyrosine kinases, and supports a model in which
an SFK acts upstream of PRL-3 to cause its phosphorylation in
vivo. Together, these observations demonstrate that Src is both
sufficient and necessary to promote phosphorylation of endoge-
nous PRL-3 in SW480 cells, although they do not rule out the
possibility that other kinases may also serve this role in other
contexts. Indeed, the presence of weak but detectable PRL-3
tyrosine phosphorylation in SYF cells (Figure 2B) suggests that
Figure 2. Src is required for PRL-3 tyrosine phosphorylation in cells. A) SW480 cells were co-transfected with both WT PRL-3 tagged with
streptavidin binding protein (SBP) and WT Src in the absence of pervanadate, and then analyzed for phosphotyrosine by western blot following pull
down with streptavidin beads. Src kinase activity was evaluated by analysis of the Src autophosphorylation site, Y416. B) WT PRL-3 was transfected
into mouse embryo fibroblasts in which expression of Src, Yes and Fyn was simultaneously ablated genetically (SYF cells) or into SYF cells into which
only Src had been reintroduced (SYF+Src). Cells were treated with pervanadate (VO4) and the phosphorylation of PRL-3 on tyrosines was then
analyzed by western blot following pull down of PRL-3. C) SW480 cells were treated with the Src family kinase inhibitor SU6656 (10 mM or 1 mM, 1 h)
prior to treatment with pervanadate and western blot analysis for PRL-3 and phosphotyrosine.
doi:10.1371/journal.pone.0064309.g002
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kinases other than Src, Yes or Fyn can also play this role to some
extent.
PDGF stimulates PRL-3 phosphorylation in a Src-
dependent manner
To determine whether PRL-3 could be phosphorylated in
response to a physiological stimulus, we treated SW480 cells with
platelet-derived growth factor (PDGF), the receptors for which
contribute to aspects of tumor development [28-30]. Figure 3
shows a 2.5-fold increase in endogenous PRL-3 phosphorylation in
response to PDGF, suggesting that PRL-3 may constitute an
important downstream mediator of PDGF signaling. Further,
ablation of Src expression using siRNA or inhibition of Src activity
using the Src inhibitor SU6656 (5 mM, 1 h) blocked PDGF-
induced PRL-3 phosphorylation, supporting a model in which
PDGF induces the phosphorylation of PRL-3 via Src. Autophos-
phorylation of Src at tyrosine 416 was evaluated as a marker of Src
kinase activity.
Residue 53 is the major site of PRL-3 tyrosine
phosphorylation
To identify the site(s) of tyrosine phosphorylation on PRL-3, we
first analyzed the PRL-3 sequence using NetPhos 2.0, which
predicted high probabilities for phosphorylation on tyrosine
residues 14, 53, and 126 (Y14, Y53, Y126, Figure 1A). Based on
this analysis we generated point mutants of PRL-3 in which
tyrosines 14, 53 or 126 were mutated individually to non-
phosphorylatable phenylalanines (Y14F, Y53F or Y126F, respec-
tively). Each of these mutants, as well as WT and All_F, was then
expressed in SW480 cells. After pervanadate treatment, PRL-3
proteins, which were also tagged with streptavidin-binding protein
(SBP), were precipitated using streptavidin-Sepharose and then
immunoblotted for total PRL-3 or for phosphotyrosine.
Similar to endogenous PRL-3, tyrosine phosphorylation of
exogenous PRL-3 was also revealed by pervanadate treatment
(Figure 4A). As seen previously, the All_F mutant was not
phosphorylated. The band appearing in the All_F + pervanadate
lane is a non-specific band (NSB), which appears in all lanes at a
slightly faster mobility than PRL-3, and can be clearly distin-
guished from phospho-PRL-3 (see Y53F lane). Mutation of Y53
almost completely prevented the phosphorylation of PRL-3
(Figure 4A), indicating that this residue is the major site for this
modification. The small amount of residual phosphorylation
indicates that at least one other site can also be phosphorylated,
albeit to a much lesser extent. Mutation of Y126 reduced overall
phosphorylation marginally, indicating that this residue can be
phosphorylated but is not the preferred site. Y126 may account for
the residual phosphorylation seen with the Y53F mutant.
Mutation of Y14 had no detectable effect on PRL-3 phosphor-
ylation, thereby ruling out this site as a major target for tyrosine
phosphorylation in vivo.
To confirm these observations, we generated a complementary
set of PRL-3 mutants in which only a single tyrosine was present in
each, at residues 14, 53 or 126, while the remaining five tyrosines
were mutated to phenylalanines (14Y-only, 53Y-only or 126Y-
only). As shown in Figure 4B, 53Y-only supported phosphoryla-
tion comparable to that seen with WT PRL-3, a finding consistent
with this site as the major site of phosphorylation, and with the
nearly complete loss of phosphorylation of the Y53F mutant
shown in Figure 4A. Similarly, a small amount of phosphorylation
was detectable with the 126Y-only mutant, consistent with the
data shown in Figure 4A. Collectively, these observations
demonstrate that endogenous PRL-3 can be phosphorylated on
tyrosines in vivo, and that phosphorylation likely occurs almost
exclusively on Y53 and to a far smaller extent on Y126. Based on
these results, we focused our functional analyses on PRL-3 Y53F.
Figure 3. PDGF stimulates PRL-3 phosphorylation in a Src-
dependent manner. Phosphorylation of endogenous PRL-3 in SW480
cells was evaluated as in Figure 1B following PDGF stimulation (20 ng/
mL, 20 min). siRNA was used to reduce Src expression (‘‘Src siR’’), or the
Src inhibitor SU6656 (5 mM) was used to inhibit Src activity (‘‘SU’’).
Phosphotyrosine on PRL-3 was analyzed five days after siRNA
transfection, and the degree of phosphorylation compared to that
seen with control nontargeted siRNA (‘‘Cont. siR’’).
doi:10.1371/journal.pone.0064309.g003
Figure 4. Residue 53 is the primary site of PRL-3 tyrosine
phosphorylation. A) To identify the sites of phosphorylation, SW480
cells were transfected with expression constructs encoding wild-type
PRL-3 or mutants in which all six or specific individual tyrosines were
mutated to nonphosphorylatable phenylalanines (All_F, Y14F, Y53F,
Y126F). Each was expressed as a protein fused to streptavidin-binding
protein (SBP). Following pervanadate treatment, SBP-tagged PRL-3 was
precipitated using streptavidin-Sepharose, and analyzed by SDS-PAGE
and western blot for either PRL-3 or phosphotyrosine. A non-specific
band (NSB) appears in all VO4-treated lanes at slightly a faster mobility
than PRL-3. B) Conversely, PRL-3 mutants in which all but one tyrosine
was mutated to phenylalanine, and which therefore contain a single
tyrosine only at position 14 (14Y-only), 53 (53Y-only) or 126 (126Y-only),
were analyzed similarly.
doi:10.1371/journal.pone.0064309.g004
Src Regulation of PRL-3
PLOS ONE | www.plosone.org 5 May 2013 | Volume 8 | Issue 5 | e64309
PRL-3 promotion of invasion and cell motility requires
Y53
Our results show that Src kinase activity leads to the tyrosine
phosphorylation of PRL-3, primarily on Y53. Both PRL-3 and Src
play well-established roles in cell motility, and both are implicated
by numerous correlative and functional studies in tumor invasion
and metastasis [1-3,31]. This suggests that Src may regulate the
invasion- and metastasis-associated functions of PRL-3 through
phosphorylation. To begin to address this possibility, we first
determined whether phosphorylation of PRL-3 affects its ability to
promote invasion. SW480 cells stably expressing wild-type PRL-3
or a mutant lacking tyrosine 53 (Y53F) were evaluated for their
ability to invade through Matrigel. Figure 5A shows that wild-type
PRL-3 promoted a 4-5-fold increase in the invasiveness of SW480
cells, whereas the Y53F mutant promoted an increase of only 40%
that of WT, indicating that phosphorylation at this site is likely
required for full PRL-3-induced invasion. In each assay, at least 20
control cells invaded.
We next determined whether the phosphorylation-deficient
mutant of PRL-3 was still able to promote cell motility, which is a
necessary component of the invasive phenotype. Because SW480
cells are not suitable for this type of analysis, we used H1299 cells,
which have suitable properties of basal adhesiveness and motility.
Cells were transiently transfected with EGFP-tagged PRL-3 or the
Y53F mutant. The average velocities of individual cells were
measured and compared to the velocities of cells expressing EGFP
only. Figure 5B shows that wild-type PRL-3 significantly increased
the average speed of H1299 cells by two fold, whereas the Y53F
mutant had no significant effect. Together with the data shown in
Figure 5A, these results confirm that PRL-3 promotes both
invasion and motility, and that tyrosine 53 is crucial to both
phenotypes, presumably due to a requirement for the phosphor-
ylation event that occurs at this site.
PRL-3 requires the activity of a Src family kinase to
promote invasion and RhoC activation
Our data show that PRL-3 is phosphorylated downstream of
Src (Figures 1, 2 and 3), that Y53 is the major site of tyrosine
phosphorylation (Figure 4) and that Y53 is required for full
promotion of invasion (Figure 5A), presumably because Y53 must
be phosphorylated. These observations predict that PRL-3
requires Src activity to promote invasion and possibly other
functions. To test this hypothesis, we next determined whether
inhibition of Src activity affected the ability of PRL-3 to promote
invasion. The ability of SW480 cells stably expressing wild-type
PRL-3 to invade through Matrigel was evaluated in the presence
Figure 5. PRL-3 promotion of invasion and cell motility requires an intact Y53. A) SW480 cells stably expressing WT PRL-3 (WT) or a
phosphorylation-deficient mutant lacking tyrosine 53 (Y53F) were subjected to Matrigel invasion assays. Data from three independent assays are
shown. For each sample, 5x104 cells were placed in the top chamber in the absence of serum; the bottom chamber contained medium
supplemented with 10% serum. After 72 h, invaded cells were fixed, stained and counted. Equal expression of WT HA-tagged PRL-3 and the Y53F
mutant was confirmed by HA blot. B) H1299 cells were transiently transfected with EGFP-tagged PRL-3, the Y53F mutant or vector only. The motility
rate of individual cells was evaluated using a BioStation IM live cell recorder. Data shown are from three independent assays, and include a total of at
least 35 cells for each sample. Images of representative cells expressing each EGFP-tagged protein are shown below the graph. All images were
captured under identical microscopic and photographic settings. Data in both A and B are shown +/2 SEM, and p-values were calculated using a
two-tailed Student’s t-test.
doi:10.1371/journal.pone.0064309.g005
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or absence of the Src family kinase inhibitor SU6656. PRL-3-
induced Matrigel invasion was blocked by SU6656 in a dose-
dependent manner, with 90% inhibition seen at 5 mM (Figure 6A).
At this concentration, invasion was reduced to a level comparable
to that seen with phosphatase-inactive PRL-3 C104S or empty
vector. We have shown previously that PRL-3 promotes activation
of the small GTPase RhoC [4], which contributes to tumor cell
motility and invasion through regulation of the actin cytoskeleton
[32-34]. Figure 6B shows a representative RhoC-GTP assay in
which active RhoC-GTP was selectively pulled down from cell
lysates and quantitated by western blot analysis. Data from at least
three independent pull down assays are summarized in Figure 6C,
which shows that inhibition of Src family kinases with SU6656
blocked PRL-3-induced RhoC activation, reducing it from 5-fold
to basal levels. Together these observations indicate that tyrosine
phosphorylation and Src activity are both required for PRL-3-
dependent biological functions, and that Src regulation of PRL-3
may be part of an important signaling pathway contributing to
tumor invasion and metastasis.
Discussion
Numerous correlative studies in tumors of the colon, stomach,
breast, pancreas and ovaries have shown that PRL-3 expression
increases with tumor progression (reviewed in [2,35]). Further,
PRL-3 expression also correlates with tumor clinicopathology and
disease outcome in a variety of tumor types [36–40]. These
correlative studies are supported by numerous functional studies
(reviewed in [1,3]). In cell culture and mouse model systems,
ectopic expression of PRL-3 promotes cell motility and invasion
[4,41–45]. Conversely, silencing of endogenous PRL-3 by siRNA
inhibits both invasion and metastasis in model systems [8,46].
Further, PRL-3 knockdown mice develop significantly fewer colon
tumors in response to azoxymethane than wild-type mice [47],
directly demonstrating a role for PRL-3 in tumor formation in vivo.
Collectively, these observations support a causal role for PRL-3 in
tumor invasion and metastasis and have led to the frequent
characterization of PRL-3 as a "metastasis-associated tyrosine
phosphatase". Our data suggest that these biological functions of
PRL-3 are regulated by a Src family tyrosine kinase, and that this
Figure 6. PRL-3 requires the activity of a Src family kinase to promote invasion and RhoC activation. A) SW480 cells expressing WT PRL-
3 were subjected to Matrigel invasion analysis as in Figure 5. The Src family kinase inhibitor SU6656 was added to both the top and bottom chambers
at the indicated concentrations. Cells expressing phosphatase-inactive PRL-3 (C104S) served as a negative control. Data are shown normalized to
basal levels of invasion of vector-expressing cells. Results from four assays are shown +/2 SD. B) SW480 cells expressing WT PRL-3 were treated with
the Src inhibitor, SU6656, and analyzed for levels of active, GTP-bound RhoC using a Rhotekin-RBD pull down assay. Images from a representative
assay are shown. Lanes containing samples not relevant to this work have been removed. All panels were taken from the same assay using the same
photographic exposure time. Phosphatase-inactive PRL-3 (C104S) served as a negative control. C) Data quantitated from at least three pull down
assays as in panel B are shown +/2 SEM.
doi:10.1371/journal.pone.0064309.g006
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may be due to Src-mediated phosphorylation of tyrosine 53, a
residue that we show here is both the major site of tyrosine
phosphorylation and a requirement for full PRL-3 activity.
Specifically, we have shown that: 1) Src itself can phosphorylate
PRL-3 directly in vitro, 2) endogenous PRL-3 is tyrosine
phosphorylated, 3) Src is required for tyrosine phosphorylation
of PRL-3, 4) PDGF can stimulate PRL-3 phosphorylation in a Src-
dependent manner, 5) of the six tyrosines in PRL-3, Y53 is the
major site of phosphorylation, 6) Y53 is required for PRL-3
promotion of motility and invasion, and 7) PRL-3 requires the
activity of a Src family kinase to fully promote motility, invasion
and RhoC activation. Collectively these results support a model in
which Src causes phosphorylation of PRL-3 on Y53 to promote its
pro-invasion functions, and suggest for the first time that the
metastasis-associated tyrosine phosphatase PRL-3 may itself be
regulated by post-translational modification.
There are precedents for regulation of tyrosine phosphatases by
their own tyrosine phosphorylation. PTP1B, LMW-PTP and Shp-
2 are each reported to be phosphorylated on tyrosines with
functional consequences of that modification [16-22]. In vitro
analyses suggest that phosphorylation may directly affect the
catalytic activity of both LMW-PTP and PTP1B, although the
structural changes that are presumably responsible for this are not
clear. In the case of Shp-2, tyrosine phosphorylation is thought to
induce the formation of intramolecular bonds between phospho-
tyrosines and internal Src homology-2 (SH2) domains, thus
exposing the active site and increasing catalytic activity. Phos-
phorylation of LMW-PTP has also been shown potentially to
create a binding site for the adapter protein Grb2 [17], suggesting
a role for the phosphatase as a scaffolding protein in Ras signaling
pathways.
It is not yet clear by what mechanism phosphorylation affects
the function of PRL-3, although several possibilities exist. As with
LMW-PTP, PTP1B and Shp-2, phosphorylation of PRL-3 at Y53,
which lies in the second alpha-helical domain adjacent to the
active site [48], may directly affect catalytic activity, or influence
subcellular localization. Although we have not observed any
obvious effects of phosphorylation on subcellular localization by
confocal immunofluorescence microscopy (data not shown), it is
possible that phosphorylation induces more subtle differences that
are nevertheless functionally important, such as restriction to
specific membrane-binding sites. As with LMW-PTP, phosphor-
ylation of PRL-3 could also create new binding sites for proteins
containing SH2 domains, such that PRL-3 may act as a
membrane-associated scaffolding protein as well as a phosphatase.
Further, given that tyrosine 53 is found in all three PRL proteins,
and that the surrounding sequence is highly conserved, it will be of
interest to determine whether a similar functional relationship
exists between PRL-1 or PRL-2 and Src. It has also been shown
recently that PRL-3 associates with and promotes the activity of
the GTPase Arf1 at the Golgi [42], suggesting that PRL-3 may
promote cell motility by affecting vesicular trafficking and protein
secretion at the leading edge. Interestingly, both Golgi localization
and Arf1 association of PRL-3 depend on the sequence MKYE
[42], which includes tyrosine 126. Although we have focused here
on tyrosine 53, we also detected phosphorylation of tyrosine 126
(Figure 4B), suggesting that PRL-3/Arf1 activities may be
modulated by phosphorylation of this site. Future studies will
address this issue.
A structural feature unique to PRL PTPs is that they form non-
covalent trimers in vitro and in vivo [49,50], suggesting that
quaternary interactions may be required for full catalytic activity,
and that disruption of this structure, possibly through phosphor-
ylation, may affect function. However, it seems unlikely that the
trimerization of PRL-3 is affected by phosphorylation at tyrosine
53, which is distant from the trimer interface, based on the highly
homologous sequence of PRL-1 [49,50]. Now that we have
established for the first time that tyrosine phosphorylation is an
important process affecting the biological functions of PRL-3, it
will be important next to further define the structural and/or
biochemical mechanisms that produce these effects.
There is an increasing appreciation that signal transduction
occurs in the context of complex feedback loops rather than a simple
unidirectional flow of linear pathways [51-53]. For example, EGF
stimulation of EGFR activates the Ras.Raf.MEK pathway,
which in turn regulates expression of both EGFR and its ligands
[54]. Together with our observations here, previous reports
supporting a functional connection between Src and PRL
phosphatases also suggest a reciprocal relationship between these
two proteins. Inhibition of PRL-1 expression has been shown to
reduce expression of both Src and the important Src substrate,
p130Cas [55], suggesting that PRL-1 transcriptionally activates key
components of Src signaling pathways, and may promote both
normal and aberrant Src-dependent phenotypes. Interestingly,
PRL-3 inhibits expression of the Src regulatory protein c-Src kinase
(Csk) [43], which normally blocks the activation of Src by
phosphorylating it on tyrosine 528. Together these observations
suggest that PRL PTPs may upregulate Src signaling by distinct but
complementary mechanisms. Both models place PRL phosphatases
upstream of Src expression and activity. In addition, our results
suggest that Src may also act upstream of PRL-3, affecting PRL-3
functions through tyrosine phosphorylation. In addition, such a
functional link suggests that PRL-3 and Src may cooperate in colon
carcinoma, in which the expression of PRL-3 [2] as well as the
expression and activity of Src [56,57] all increase with advancing
disease. If so, evaluation of expression of PRL-3 and Src together in
colon tumors may help predict more aggressive disease and poor
prognosis, and may identify patients who could benefit from more
aggressive treatment options. We are currently addressing these
questions, the results of which will be described elsewhere.
By functionally linking PRL-3 and Src, which individually play
established roles in cell motility, invasion and metastasis, our
model helps to better define the biochemical mechanisms of these
important aspects of tumor progression. In light of recent progress
towards clinically-relevant Src inhibitors (reviewed in [31,58]) and
increasing effort devoted to identifying and characterizing
inhibitors of PRL-3 (reviewed in [2]), our work offers new insights
into the development and clinical application of molecularly
targeted cancer therapeutics. Our results suggest that PRL-3 may
mediate some tumorigenic functions of Src, particularly those
associated with control of small GTPases, such as RhoC, and
tumor cell motility and invasion. If so, PRL-3 expression, which
increases with progression in many tumor types, may help identify
tumors that will be sensitive to Src inhibitors. Similarly, Src
expression may reflect sensitivity to PRL-3 inhibitors when
sufficiently selective and potent ones become available. In this
regard, it would be interesting to determine whether expression
levels of Src and PRL-3 correlate in tumors, suggesting a general
upregulation of the Src . PRL-3 signaling axis that we have
proposed here, and whether such a correlation has implications for
the aggressiveness of the disease, or patient outcome. We are
working to address this possibility.
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